Effects of dapagliflozin on cardiovascular outcomes in type 2 diabetes

Study protocol of a randomized controlled trial

Dong Yin, MM, Yuan Hui, MM, Chuanhui Yang, MM, Yi Xu, MM*©

Abstract

Background: Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. This current research is a double blinded, randomized, and prospective trial to determine the effect of dapagliflozin on cardiovascular outcomes in type 2 diabetes.

Methods: This randomized controlled, double-blinded, single center trial is carried out according to the principles of Declaration of Helsinki. This present study was approved in institutional review committee of the Lianyungang Hospital affiliated to Xuzhou Medical University (LW-20200901001). All the patients received the informed consent. Diabetic patients were randomized equally to receive 28-week treatment with dapagliflozin or matching placebo. The major outcome of our current study was the change in the level of hemoglobin A1c (HbA1c) from the baseline to week 28. Secondary outcome measures contained the levels of fasting blood glucose, the mean change in seated systolic and diastolic blood pressure, body weight, and the mean change in calculated average daily insulin dose in patients treated with insulin at baseline, the other laboratory variables, and self-reported adverse events. The P < .05 was regarded as statistically significant.

Results: We assumed that the dapagliflozin administration in patients with type 2 diabetes would reduce HbA1c, body weight, systolic blood pressure, and achieve the goal of glycemic control, without adversely impacting cardiovascular risk.

Trial registration: This study protocol was registered in Research Registry (researchregistry5987).

Abbreviations: CVD = cardiovascular disease, HbA1c = hemoglobin A1c, SGLT2 = sodium glucose co-transporter 2.

Keywords: cardiovascular outcomes, dapagliflozin, randomized controlled trial, SGLT2, sodium–glucose cotransporter-2, study protocol, type 2 diabetic patients

1. Introduction

The cardiovascular disease (CVD) is still a direct and major cause of incidence rate and mortality among type 2 diabetic patients. In comparison with the non-diabetic people, the risk of cardiovascular disease is about 2 times that of non-diabetic patients.[11] Chronic hyperglycemia can cause the complications of microvascular and macrovascular.[2,3] In view of the increased health risk of complications and the clinical consequences,[4] in order to effectively treat type 2 diabetes, it is necessary to control blood glucose, including strategies to treat the risk of hypertension, obesity as well as cardiovascular disease.[5,6] The European Medicines Agency and the U.S. Food and Drug Administration have issued guidelines requiring the novel treatments for diabetes to exclude an unacceptable increase in the risk of cardiovascular disease.[7] We need effective and safe treatment strategies to control the hyperglycemia and increase the clinical benefits.[8,9]

The familiarly utilized antidiabetic drugs (involving non-sulfonylurea secretagogues, sulfonylureas,[10,11] and thiazolidinediones, metformin, glucagon-like peptide-1 analog,[12] dipeptidyl peptidase-4 inhibitors as well as the α-glycosidase inhibitors) are insulin-dependent in their efficacy.[13] In the development of type 2 diabetes, when the function of the islet β-cells decreases, they become less effective.[14] Thiazolidinediones and sulfonylureas contribute to the weight gain and then in-depth worsen the insulin resistance.[15] Not surprisingly, about two-thirds of type 2 diabetes patients fail to achieve their goal of blood glucose control under the regular treatment. In contrast, as the inhibitor of sodium glucose co-transporter 2 (SGLT2) with highly selective,[16] Dapagliflozin is a kind of selective inhibitor of sodium–glucose cotransporter-2 (SGLT2), it reduces the levels of blood glucose via decreasing the reabsorption of glucose in kidney,[17] it does not depend on the effect or secretion of insulin, leading to enhanced the urine glucose excretion, accompanied by caloric loss and osmotic diuresis.[18] In the clinical trials, dapagliflozin has been well tolerated as the monotherapy or in combination with insulin, sulfonylureas and metformin.[19,20] The action mechanism of dapagliflozin can affect many risk factors for cardiovascular disease, especially lowering...
the blood pressure, weight loss,[21] decreasing the serum uric acid and albuminuria levels, lowering the waist circumference, and decreasing the inherent risk of hypoglycemia.[22,23]

This current research is a double blinded, randomized, and prospective trial to determine the influences of the dapagliflozin on the cardiovascular results of type 2 diabetes.[24,25] We assumed that adding the dapagliflozin to the medication in the type 2 diabetes patients would reduce CVD risk and achieve the goal of glycemic control.[26,27]

2. Material and method

This randomized controlled, double-blinded, single center trial is implemented on the basis of the Declaration of Helsinki. This present study was approved in institutional review committee of the Lianyungang Hospital affiliated to Xuzhou Medical University (LW-20200901001). All the patients received the informed consent. It was also registered at the Research Registry (researchregistry5987).

2.1. Eligibility criteria

Inclusion criteria were the female or male patients with type 2 diabetes, and the age range is between 30 and 79 years, with an inadequate glycemic control, which were defined as HbA1c ≥9.5% and ≥6.6%. Subjects were required to register C-peptide ≥0.27 nmol/l, the rate of estimated glomerular filtration less than 150 ml/minute/1.73 m² and greater than 60 ml/minute/1.73 m²,

![Consolidated standards of reporting trials statement flow diagram.](Image)
the urinary albumin to the ratio of creatinine less than 300 mg/g, and the index of body mass ≤45.0 kg/m², with an insufficient control of blood pressure, which was defined as the diastolic blood pressure less than 105 mm Hg and ≥80 mm Hg, and/or the systolic blood pressure less than 165 mm Hg and ≥130 mm Hg. Exclusion criteria included: a recent history of cardiovascular events, gestational diabetes, unstable renal disease, retinopathy, hepatic, or hematologic disease.

2.2. Randomization and blinding

Each study group had an equal number of envelopes and the envelopes were produced via a research assistant through utilizing a computer-based random number generator who did not participate in any follow-up studies or contact with other study group members during the research period. He has prepared 150 identical, sealed, sequentially numbered, and opaque envelopes, with 30 envelopes containing the instructions for each group. These above envelopes have been submitted to the principal investigator for filing (Fig. 1).

2.3. Intervention and control

This is a placebo-controlled, double-blind, randomized trial, with a treatment of 28 weeks and a follow-up of 30 days. Then, the eligible patients in the introduction stage were randomly divided into 4 treatment groups with a blind manner (in a ratio of 1:1:1:1). Patients were equally given once-daily doses of dapagliflozin (5 mg, 10 mg, 20 mg, or 50 mg, respectively), or were given a matched placebo dose in combination with an established stable background treatment. Safety and efficacy were assessed at all study visits, the other laboratory variables, and self-reported adverse events. A value of \( P < .05 \) is considered as the significant in statistics.

2.4. Outcome measures

All the primary and critical secondary impact variables are pre-specified. The primary influencing variable was HbA1c change from baseline to week 28. At 28 weeks, the 5 primary secondary influencing variables involved:

1. the change of overall weight from baseline;
2. the change of 24-hour ratio of urine glucose to creatinine;
3. the average change of sitting diastolic and systolic blood pressure from baseline;
4. the change of fasting blood glucose from the baseline;
5. the average change of calculated daily dose of insulin in the insulin treated patients at baseline.

The vital signs, laboratory parameters, and data on adverse events were collected for the evaluation of the long-term tolerability and safety of dapagliflozin for 28 weeks.

2.5. Statistical analysis

With the Statistical Package for Social Sciences, the statistical analysis was implemented (SPSS for Windows, release 12.0; SPSS Inc., Chicago, IL). The statistical analysis was carried out via independent experts and it was not participated in the research program. The values of mean (range) and median were presented. Non-paired t-test was utilized for the numerical data of normal distribution. Non-parametric simulation was utilized where appropriate. The \( x^2 \) test was utilized to compare the categorical variables. A value of \( P < .05 \) is considered as the significant in statistics.

3. Discussion

With the growth of age, type 2 diabetes patients usually treated through the antidiabetic drugs combining with other concomitant drugs to control comorbidities, for instance, obesity, hypertension and the cardiovascular disease. It is a recognized problem that type 2 diabetes patients possess an enhanced possibility of cardiovascular disease. Dapagliflozin is a kind of selective inhibitor of sodium-glucose co-transporter-2 that decreases the reabsorption of renal glucose with an insulin-independent mode. We attempted to determine the influence of dapagliflozin on lowering HbA1c, reducing systolic blood pressure and BW in patients at high risk for future cardiovascular disease events.

Author contributions

Conceptualization: Dong Yin.
Data curation: Dong Yin.
Formal analysis: Dong Yin.
Funding acquisition: Yi Xu.
Investigation: Dong Yin.
Methodology: Yuan Hui.
Project administration: Yuan Hui, Yi Xu.
Resources: Yi Xu.
Software: Chuanhui Yang.
Supervision: Chuanhui Yang, Yi Xu.
Validation: Yuan Hui, Chuanhui Yang.
Visualization: Yuan Hui.
Writing – original draft: Dong Yin.
Writing – review & editing: Chuanhui Yang, Yi Xu.

References

[1] Sonesson C, Johansson PA, Johnsson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 2016;15:37.
[2] List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650–7.
[3] Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;33:2217–24.
[4] Bailey CJ, Iqbal N, T’joen C, et al. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomised-controlled trial of low-dose range. Diabetes Obes Metab 2012;14:951–9.
[5] Wilding JP, Norwood P, T’joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656–62.
[6] Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223–33.
[7] Hennekens CH, Hebert PR, Schneider WR, et al. Academic perspectives on the United States Food and Drug Administration’s guidance for industry on diabetes mellitus. Contemp Clin Trials 2010;31:411–3.
[8] Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020–31.
[9] Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012;66:446–56.
[10] Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012;156:403–15.

[11] Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2012;14:990–9.

[12] Bailey CJ, Gross JL, Herricksen D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013;11:43.

[13] Ripsin CM, Kang H, Urban RJ. Management of blood glucose in type 2 diabetes mellitus. Am Fam Physician 2009;79:29–36.

[14] Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802–12.

[15] Clar C, Gill JA, Court R, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012;2.

[16] Sun YN, Zhou Y, Chen X, et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open 2014;4:e004619.

[17] Rosenstock J, Frias J, Pall D, et al. Effect of erugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 2018;20:520–9.

[18] Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014;16:159–69.

[19] Leiter LA, Cefalu WT, de Brum TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014;62:1252–62.

[20] Schumm-Draeger PM, Burgess L, Koranyi L, et al. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial. Diabetes Obes Metab 2015;17:42–51.

[21] Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12:90–100.

[22] Rosenstock J, Vico M, Wei L, et al. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473–8.

[23] Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 2014;30:204–21.

[24] Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of erugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 2019;21:1027–36.

[25] Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014;37:740–50.

[26] Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther 2014;16:137–44.

[27] Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962–71.